Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zentalis Pharmaceuticals, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 194,465 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 57,100 · Balance 194,465 F1: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Imago BioSciences, Inc.
Report date January 11, 2023 · Filed January 11, 2023
Section 16 reporting ended · disclosed 2023-01-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.20 · Expires 2031-02-04 | Direct | 0 |
Reported balance
After 2023-01-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-11 · Disposition to issuer · Disposed 119,047 · Balance 0 F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2031-07-14 | Direct | 0 |
Reported balance
After 2023-01-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-11 · Disposition to issuer · Disposed 23,809 · Balance 0 F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.65 · Expires 2032-05-31 | Direct | 0 |
Reported balance
After 2023-01-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-11 · Disposition to issuer · Disposed 11,904 · Balance 0 F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 20:07 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 57,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001843119-26-000003 · wk-form4_1781813217.xml · nonDerivative · entry 1 Kariuki Enoch · CIK 0001843119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,465 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:14 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 57,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-25-000131 · wk-form4_1750277634.xml · nonDerivative · entry 1 Kariuki Enoch · CIK 0001843119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,365 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 17, 2026 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 21:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 41,581 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-24-000143 · wk-form4_1719004175.xml · nonDerivative · entry 1 Kariuki Enoch · CIK 0001843119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,762 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 21, 2025 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 21:02 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 16,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-23-000143 · wk-form4_1686949344.xml · nonDerivative · entry 1 Kariuki Enoch · CIK 0001843119 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,181 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2024 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| January 11, 2023 Filed Jan 11, 2023 16:19 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,904 | Not disclosed Strike: $15.65 | Not disclosed |
DisclosureSEC source: 0000899243-23-001607 · doc4.xml · derivative · entry 3 Kariuki Enoch · CIK 0001843119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,904 shares Expires 2032-05-31 F1 · price: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. F1 · derivative.exercise_date: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. Read SEC document |
| January 11, 2023 Filed Jan 11, 2023 16:19 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | Disposition to issuerStock Option (Right to Buy) · Derivative | 23,809 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0000899243-23-001607 · doc4.xml · derivative · entry 2 Kariuki Enoch · CIK 0001843119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,809 shares Expires 2031-07-14 F1 · price: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. F1 · derivative.exercise_date: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. Read SEC document |
| January 11, 2023 Filed Jan 11, 2023 16:19 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | Disposition to issuerStock Option (Right to Buy) · Derivative | 119,047 | Not disclosed Strike: $4.20 | Not disclosed |
DisclosureSEC source: 0000899243-23-001607 · doc4.xml · derivative · entry 1 Kariuki Enoch · CIK 0001843119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 119,047 shares Expires 2031-02-04 F1 · price: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. F1 · derivative.exercise_date: On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. Pursuant to the Merger Agreement, each option to purchase common stock of the Issuer, whether vested or unvested, outstanding immeditately prior to the effective time of the Merger, were exchanged for a cash payment equal to (x) the aggregate number of shares of the Issuer's common stock subject to such option, multiplied by (y) the excess, if any, of $36.00 over the per share exercise price under such option. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:21 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 21,817 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000120 · wf-form4_165489245326140.xml · nonDerivative · entry 1 Kariuki Enoch · CIK 0001843119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,817 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 8, 2023 or (b) the next occurring annual meeting of the Company's stockholders, subject to the Reporting Person's continued service on the Board of Directors through such vesting date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 16:39 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | GrantStock Option (Right to Buy) · Derivative | 11,904 | $0.00 Strike: $15.65 | $0.00 |
DisclosureSEC source: 0001567619-22-012286 · doc1.xml · derivative · entry 1 Kariuki Enoch · CIK 0001843119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,904 Underlying: Common Stock · 11,904 shares Expires 2032-05-31 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual meeting in 2023 of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 16:11 UTC | Imago BioSciences, Inc. IMGO · Entity 15490 | GrantStock Option (Right to Buy) · Derivative | 23,809 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001567619-21-013642 · doc1.xml · derivative · entry 1 Kariuki Enoch · CIK 0001843119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,809 Underlying: Common Stock · 23,809 shares Expires 2031-07-14 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares initially subject to the option will vest on each monthly anniversary measured from July 15, 2021 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 14:41 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 42,000 | $0.00 Strike: $39.47 | $0.00 |
DisclosureSEC source: 0001725160-21-000029 · wf-form4_161296807661323.xml · derivative · entry 1 Kariuki Enoch · CIK 0001843119 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2031-02-08 F1 · derivative.exercise_date: The options vest and become exercisable in substantially equal monthly installments over the 36 months following the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.